Impact of severe haemophilia A on patients' health status: results from the guardian™ 1 clinical trial of turoctocog alfa (NovoEight®)

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2516|21|4|451-457

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.21, Iss.4, 2015-07, pp. : 451-457

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long‐term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial

By  

HAEMOPHILIA, Vol. 21, Iss. 5, 2015-09 ,pp. : e436-e439

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial

By  

HAEMOPHILIA, Vol. 1351-8216, Iss. 5, 2015-09 ,pp. : e436-e439

John Wiley & Sons Inc

Access to resources Recommend Favorite

The pharmacokinetics of a B‐domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 3, 2015-03 ,pp. : 370-379

John Wiley & Sons Inc

Access to resources Recommend Favorite

Health‐related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials

By  

HAEMOPHILIA, Vol. 21, Iss. 5, 2015-09 ,pp. : e344-e358

John Wiley & Sons Inc

Access to resources Recommend Favorite

Health‐related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials

By  

HAEMOPHILIA, Vol. 1351-8216, Iss. 5, 2015-09 ,pp. : e344-e358

John Wiley & Sons Inc

Access to resources Recommend Favorite